share_log

Avalo Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Avalo Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Avalo Therapeutics | PRE 14A：並購重組委托聲明
美股sec公告 ·  06/07 07:06
Moomoo AI 已提取核心訊息
Avalo Therapeutics, Inc. has announced its upcoming Annual Meeting, which will be conducted virtually via live audio webcast on an unspecified date in 2024. The meeting will address several key corporate matters, including the election of seven directors nominated by the board for a one-year term, approval of common stock issuance for various purposes, and the ratification of Ernst & Young LLP as the company's independent accounting firm for the fiscal year ending December 31, 2024. Additionally, stockholders will vote on the approval of the Fourth Amended and Restated Equity Incentive Plan and the Amended and Restated Employee Stock Purchase Plan, both of which propose to increase available shares and extend automatic annual increases. The company will also seek authorization to adjourn the meeting if necessary to solicit additional votes.
Avalo Therapeutics, Inc. has announced its upcoming Annual Meeting, which will be conducted virtually via live audio webcast on an unspecified date in 2024. The meeting will address several key corporate matters, including the election of seven directors nominated by the board for a one-year term, approval of common stock issuance for various purposes, and the ratification of Ernst & Young LLP as the company's independent accounting firm for the fiscal year ending December 31, 2024. Additionally, stockholders will vote on the approval of the Fourth Amended and Restated Equity Incentive Plan and the Amended and Restated Employee Stock Purchase Plan, both of which propose to increase available shares and extend automatic annual increases. The company will also seek authorization to adjourn the meeting if necessary to solicit additional votes.
Avalo Therapeutics，Inc.宣佈即將舉行的年度會議將於2024年未指定日期通過實時音頻網絡廣播進行。 該會議將處理幾項關鍵企業事項，包括選舉由董事會提名的七名董事，任期一年，批准發行普通股以用於各種目的，以及批准Ernst & Young LLP擔任該公司獨立的會計師事務所，以審查截至2024年12月31日的財政年度報告。此外，股東還將就批准第四修正和重訂的股權激勵計劃和修訂和重訂的員工股票購買計劃進行表決，兩者都計劃增加可用股票並延長自動年度增加。如果必要，公司還將尋求授權以推遲會議以徵求額外的投票。
Avalo Therapeutics，Inc.宣佈即將舉行的年度會議將於2024年未指定日期通過實時音頻網絡廣播進行。 該會議將處理幾項關鍵企業事項，包括選舉由董事會提名的七名董事，任期一年，批准發行普通股以用於各種目的，以及批准Ernst & Young LLP擔任該公司獨立的會計師事務所，以審查截至2024年12月31日的財政年度報告。此外，股東還將就批准第四修正和重訂的股權激勵計劃和修訂和重訂的員工股票購買計劃進行表決，兩者都計劃增加可用股票並延長自動年度增加。如果必要，公司還將尋求授權以推遲會議以徵求額外的投票。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息